Dr. Elham Kazemirad | Treatment for Infectious Diseases - Department of Medical parasitology & Mycology, Tehran University of Medical Sciences , Iran
Dr. Elham Kazemirad is a renowned Associate Professor at the Department of Medical Parasitology and Mycology, Tehran University of Medical Sciences. Her research bridges clinical and molecular diagnostics, with a central focus on Treatment for Infectious Diseases. Over the years, her contributions have emphasized Treatment for Infectious Diseases across leishmaniasis, Acanthamoeba keratitis, and protozoan infections. Her work consistently explores innovative diagnostic and therapeutic strategies, reinforcing global capabilities in Treatment for Infectious Diseases. With a dynamic presence in academia, she has dedicated her career to advancing Treatment for Infectious Diseases through cutting-edge molecular biology, gene expression studies, and nanoparticle drug delivery. Dr. Kazemirad’s leadership and research continue shaping new pathways for Treatment for Infectious Diseases in both clinical and research settings.
AUTHOR PROFILE
EDUCATION
Dr. Kazemirad holds a Ph.D., M.Sc., B.Sc., and Associate Degree in Medical Parasitology and Laboratory Sciences, all from top Iranian medical universities. Her Ph.D. thesis pioneered gene profiling in Leishmania tropica and explored mechanisms of drug resistance, directly contributing to Treatment for Infectious Diseases. Throughout her academic path, Treatment for Infectious Diseases remained a core theme, evident in her early thesis on PCR diagnostics and parasite detection. Her educational foundation was rigorously rooted in scientific innovation and clinical relevance, always aimed at improving Treatment for Infectious Diseases. This background has propelled her to become a thought leader whose educational milestones support groundbreaking discoveries in the Treatment for Infectious Diseases field.
PROFESSIONAL EXPERIENCE
Dr. Kazemirad has served as an Assistant and Associate Professor, and lab supervisor, contributing significantly to Treatment for Infectious Diseases since 2014. Her clinical laboratory leadership includes molecular diagnosis of parasitic diseases, microbial keratitis, and more, always reinforcing effective Treatment for Infectious Diseases. She combines teaching, clinical, and administrative roles to shape future parasitologists and advance diagnostics. At both Tehran University of Medical Sciences and Pasteur Institute of Iran, her dedication has been a cornerstone in Treatment for Infectious Diseases. She mentors students and leads research initiatives that redefine how Treatment for Infectious Diseases is applied and understood across academic, diagnostic, and healthcare platforms.
RESEARCH INTEREST
Dr. Kazemirad’s primary research interests center on drug resistance mechanisms, molecular diagnostics, and nanomedicine—all critical for effective Treatment for Infectious Diseases. Her passion for Treatment for Infectious Diseases drives projects involving gene expression in pathogens and the development of novel therapeutics. With expertise in biotechnology, immunology, and phylogenetics, she investigates the molecular basis of resistance and innovative drug delivery systems. Treatment for Infectious Diseases is not only her research focus but her mission. By integrating bioinformatics, molecular assays, and nanoparticle therapeutics, her research contributes vital knowledge and practical tools to improve Treatment for Infectious Diseases, especially among vulnerable and immunocompromised populations.
AWARD AND HONOR
Dr. Kazemirad has been consistently recognized for her academic excellence and innovation in Treatment for Infectious Diseases. She was ranked first in multiple academic programs and received distinctions for her graduate work in drug-resistant Leishmania. Her work in Treatment for Infectious Diseases has been honored through leadership roles in scientific congresses and editorial positions in top journals. These honors reflect her relentless commitment to advancing Treatment for Infectious Diseases through translational research and public health applications. The prestigious recognition from both Iranian and international institutions underscores her profound impact on Treatment for Infectious Diseases and her standing as a key contributor in parasitological and biomedical sciences.
RESEARCH SKILL
Dr. Kazemirad is proficient in molecular diagnostics, gene expression analysis, animal modeling, and nanoparticle-based therapeutics, all pivotal for enhancing Treatment for Infectious Diseases. Her skill set includes advanced techniques such as RT-PCR, Western blotting, cloning, proteomics, ELISA, gene silencing, and next-generation sequencing. Each technique is applied to understand, monitor, and improve Treatment for Infectious Diseases. Her expertise extends to developing diagnostic platforms for Acanthamoeba and Leishmania, along with testing novel compounds and nanoparticles. Treatment for Infectious Diseases is the core of her methodological approach, combining lab innovation with clinical relevance to transform how these diseases are managed and treated across diverse populations.
PUBLICATIONS
Dr. Kazemirad has authored over 50 peer-reviewed papers, all thematically aligned with Treatment for Infectious Diseases. Her publications focus on antimony resistance, nanoparticle therapies, gene expression in pathogens, and diagnostics for parasitic diseases. Each study enhances global strategies for Treatment for Infectious Diseases, often addressing neglected tropical diseases. Her work appears in top journals such as PLOS ONE, BMC Infectious Diseases, Acta Tropica, and the Iranian Journal of Parasitology. Her contributions serve as foundational references for researchers developing new modalities in Treatment for Infectious Diseases, bridging fundamental biology and translational medicine. The consistency and depth of her publications emphasize her leadership in Treatment for Infectious Diseases.
-
Title: Contribution of epidermal growth factor (EGF) in the treatment of cutaneous leishmaniasis caused by Leishmania major in BALB/c mice
Authors: Saberi, M.; Latifi, A.; Golkar, M.; Fard-Esfahani, P.; Mohtasebi, S.; Teimouri, A.; Afshar, M.J.A.; Kazemirad, E.; Mohebali, M.
Journal: PLoS Neglected Tropical Diseases
-
Title: High Prevalence of Enterocytozoon bieneusi Genotype BEB6 in Wild Boars in Lorestan Province, Iran: Potential Source of Zoonotic Transmission
Authors: Javanmard, E.; Mohammad Rahimi, H.; Taghipour, A.; Nemati, S.; Mohebali, M.; Rezaeian, M.; Badrifar, A.; Kazemirad, E.; Mirjalali, H.
Journal: Iranian Journal of Parasitology
-
Title: Molecular Identification of Nematodes (Superfamily: Strongylida) Traced in Herbivores Excrement in the Wildlife from Western Iran
Authors: Vafaei, M.R.; Safaie, M.; Kazemirad, E.; Mirjalali, H.; Askari, Z.; Mohebali, M.; Mowlavi, G.
Journal: SSRN
-
Title: Prevalence of free-living amoebae in five rivers associated with high human activity in Tehran province, Iran
Authors: Javanmard, E.; Kazemirad, E.; Rahimi, H.M.; Mohebali, M.; Rezaeian, M.; Alimohammadi, M.; Mirjalali, H.
Journal: Journal of Water and Health
-
Title: Transcriptional alterations of virulence factors in Leishmania major clinical isolates harboring Leishmania RNA virus 2 (LRV2)
Authors: Sabeti, S.; Koosha, M.; Kazemirad, E.; Mirabedini, Z.; Mohebali, M.; Saberi, R.; Fakhar, M.; Hajjaran, H.
Journal: BMC Infectious Diseases
CONCLUSION
Dr. Elham Kazemirad’s career epitomizes dedication to the Treatment for Infectious Diseases. Through her education, research, and professional engagements, she has elevated global understanding of parasitic diseases and their therapies. Her work integrates basic science and clinical innovation to offer novel solutions for Treatment for Infectious Diseases. From academic contributions to pioneering diagnostics and therapies, her impact is profound and ongoing. She remains a key influencer in shaping policies, mentoring future scientists, and leading research that targets resistant pathogens. As Treatment for Infectious Diseases continues to challenge global health, her expertise remains vital in guiding next-generation therapeutic advancements and public health solutions